Resistome™
WHAT YOU NEED TO KNOW
Resistomeâ„¢ is a proprietary synthetic lethality platform technology which enables the rapid development of drugs that block resistance, prevent relapse, and increase the life span of patients. The platform identifies the genes/proteins responsible for resistance to targeted therapy, immune-oncology or CAR-T in a particular cancer type, thus accelerating the discovery of novel drug targets which can be selectively inhibited to combat resistance. These drug targets are then used to develop drugs which block resistance, provide the early detection of emerging resistance, and support the development of companion diagonostics for drug combination treatments.
Resistome is 100x faster and less expensive than conventional synthetic lethality technologies.
RESISTOMEâ„¢ IDENTIFIES THE GENES/PROTEINS:
-
That trigger resistance to a given drug / treatment modality.
-
Whose inhibition will provide the most significant clinical benefit.
-
Which inhibit multiple sources of oncogenic upstream signaling that cause resistance/relapse.
-
That are triggered by a drug's mechanism of action or off-target effects (toxicity).
HOW RESISTOMEâ„¢ WORKS
HOW RESISTOMEâ„¢ HELPS DRUG DEVELOPERS
-
Screening preclinical and early clinical investigational drugs will indicate genes and signaling pathways that are resonsible for drug-specific resistance.
-
Improve inclusion/exclusion criteria to enable monotherapy success in trials.
-
Guide drug combination strategies by identifying which drugs should be combined to overcome resistance and convert resistant cohorts to responsive ones, increasing the overall drug-responsive patient cohort.
HOW RESISTOMEâ„¢ HELPS CLINICAL STUDIES
-
Resistome™ reveals the specific genes and signaling pathways impacted by drugs under study.
-
Resistome™ can predict which indications will respond to monotherapy.
-
Guide drug combination strategies to increase the size of the responding patient cohort. By identifying which drugs should be combined, we can overcome resistance and convert resistant cohorts to responsive ones.
HOW RESISTOMEâ„¢ HELPS RESCUE DRUGS WHICH FAILED IN CLINICAL TRIALS
-
A resistome™ screen of investigational drugs will reveal the genes and signaling pathways specifically causing reduced efficacy and failure.
-
Guide drug combination strategies to block resistance and restore drug efficacy.
HOW CAN I REQUEST A PRESENTATION?
It would be our pleasure to explain how we help our clients to identify resistance pathways and develop novel first in class drugs to overcome resistance, or identify their drug's mechanism of action and off-target effects. Simply fill in our contact form and we'll be in touch shortly.
CAN I INVEST ?
Contact our team to discuss how you can participate in our future as we develop the company. Simply email us at enquiries@cell-response.com or fill in our contact form.
